Protein tyrosine nitration occurs under both physiological and pathological conditions 1 .
The human genome encodes 21 receptor protein tyrosine phosphatases (RPTPs) 4, 5 . Twelve of the 21 RPTPs have two catalytic PTP domains in their intracellular parts 3, 4 . While the membrane proximal PTP domains (D1) are protein tyrosine phosphatases, it has been thought that the Cterminal PTP domains (D2) lack enzymatic activity 6, 7 . Protein tyrosine phosphatase receptor type T (PTPRT) is frequently mutated in human cancers including colorectal cancer 2, 3 . We demonstrated that PTPRT knockout (KO) mice are susceptible to colon cancer 8, 9 , thereby functioning as a tumor suppressor. Interestingly, one fifth of tumor-derived mutations of PTPRT are located in the D2 pseudo-PTP domain 3 , consistent with the D2 domain also having tumor suppressor activity.
We hypothesized that the D2 domain of PTPRT may catalyze removal of other types of tyrosine modifications. In addition to phosphorylation, tyrosine residues in proteins can undergo nitration at the 3-carbon position on the phenol ring (Y-NO2) or sulfation of the hydroxyl group 10 . To test whether PTPRT regulates these modifications, we blotted brain lysates of a PTPRT KO mouse and its WT littermate with antibodies against either nitrotyrosine (N-Y) or sulfotyrosine (S-Y).
As shown in Fig. 1A , nitrotyrosine levels of several proteins were higher in the brain lysate of PTPRT KO mouse compared to the WT littermate, whereas no change in protein tyrosine sulfation was observed ( Fig. 1B) . Our attempts to identify the modified proteins were unsuccessful, but given that all D2 domains of RPTPs co-exist with the PTP domains (D1), we postulated that the tyrosine phosphatase domain (D1) could share substrates with the D2 domain.
Because previously we had identified paxillin and STAT3 as phosphatase substrates of PTPRT 8, 11 , we tested if PTPRT regulates nitration of these proteins. As shown in Fig. 1C , nitrotyrosine levels of paxillin, but not STAT3 (data not shown), were increased in brain lysates of PTPRT KO mice compared to the WT littermates. Conversely, compared to GFP control, overexpression of WT PTPRT, but not a PTPRT construct devoid of the D2 domain ( Fig. 1D ), decreases nitrotyrosine levels of paxillin ( Fig. 1E ). Together, our data suggest that the D2 domain of PTPRT is responsible for the reduced paxillin tyrosine nitration.
We further demonstrated that the recombinant D2 domain of PTPRT, purified from E. coli, directly decreases nitrotyrosine levels of full-length paxillin immunopreciptated from cell lysates in vitro ( Fig. 2 A and B) . A D2 C1400A mutant in which the cysteine cognate to the highly conserved catalytic motif of D1 phosphatases is mutated had no activity in this assay. Using a series of paxillin deletion constructs (Fig 2 A , C and D), we mapped two tyrosine residues (Y404 and Y409) in the middle part of paxillin (M-2) as substrates of the PTPRT D2 domain. Mass spectrometry analyses demonstrated in vitro denitration of the two tyrosine residues in paxillin by the D2 domain of PTPRT ( Fig. 2E and Extended Data Fig. 1 & 2) . In contrast, the D1 domain of PTPRT did not affect nitrotyrosine levels of the same substrate ( Fig. 2F ). Moreover, the purified D2 domain decreases nitrotyrosine levels of the paxillin M-2 fragment in a timedependent manner ( Fig. 2G ). Taken together, these data suggest that the PTPRT pseudo-PTP domain (D2) possesses denitrase activity that removes nitro-groups from tyrosine residues in paxillin.
To determine the enzyme kinetics of the PTPRT denitrase, we used a synthetic nitrotyrosinecontaining paxillin peptide encompassing the nitrated Y404 residue as the substrate. As shown in Fig. 3 A & B, the WT D2 domain has Km of 1.6 mM and kcat of 0.37 S -1 , whereas the D2 domain with a mutation in the putative catalytic cysteine (C1400A) has no detectable enzymatic activity.
We tested 4 recurrent tumor-derived D2 mutations for denitrase activity. Interesting, all 4 mutant proteins (P1235L, E1299G, G1394R and R1046C) had an increased Km ( Fig. 3B ), suggesting that these mutations impair binding of substrates to the D2 domain. Of note, all WT and mutant PTPRT D2 proteins were purified to near homogeneity ( Fig. 3C ).
To test if the PTPRT denitrase contributed to tumor suppression, we generated Ptprt C1400V mutant knockin mice in the C57BL/6 mouse strain using CRISPR/Cas9 genome editing ( Fig. 4A and Supplementary Fig. 3 ). We chose to mutate the catalytic cysteine to valine, because it creates a new PmlI restriction cutting site that facilitates genotyping of the mutant mice (Extended Data Fig. 3 ). Nitrotyrosine levels of paxillin were dramatically up-regulated in Ptprt C1400V/C1400V mice compared to their WT littermates (Fig. 4B ). The C1400V mutation did not affect the phosphatase activity, as the levels of pSTAT3, a known phosphatase substrate of PTPRT, did not change in Ptprt C1400V/C1400V mice compared to the WT littermates ( Fig. 4C ). The mutation also did not affect levels of PTPRT protein ( Fig. 4D ). Together, these data provide compelling evidence that the denitrase activity of PTPRT decreases paxillin tyrosine nitration in vivo.
Next, we set out to determine if the denitrase activity of PTPRT contributes to its tumor suppressor function. Given that we showed previously that PTPRT knockout mice are susceptible to AOM induced colon tumor development 8 , we treated Ptprt WT/WT , Ptprt WT/C1400V and Ptprt C1400V/C1400V with six doses of AOM. As reported previously 8 , the Ptprt WT/WT mice were highly resistant to AOM induced colon cancer and none developed any colon tumors ( and Ptprt WT/C1400V mice also developed significantly more tumors than the WT mice ( Fig. 4G , Extended Data Fig. 4 B & C). Together, these data suggest that the denitrase activity of PTPRT has a tumor suppressor function.
Although protein tyrosine nitration was identified over fifty years ago 12 , the physiological relevance of this protein modification is not clear. Protein tyrosine nitration has been detected under physiological conditions as well as in diseases including cancer, atherosclerosis, myocardial infarction, chronic obstructive pulmonary disease, diabetes, Parkinson's disease, and Alzheimer's disease 1 . It is generally believed that tyrosine nitration is a byproduct of reactive oxygen/nitrogen species 1 . Nonetheless, several studies suggest that there exist enzymes (denitrases) that remove nitration from tyrosine residues in proteins [13] [14] [15] . The identity of those enzymes however has been elusive. We demonstrate that the second catalytic domain (D2) of PTPRT is a denitrase that removes the nitro group from tyrosine residues in paxillin and that the denitrase activity of PTPRT is associated with suppression of tumor formation in two colon cancer models. These results suggest that regulation of protein tyrosine nitration plays a critical role in tumorigenesis. Lastly, our study suggests that some, if not all, of the D2 domains of RPTPs may function as denitrases as well. Cell lysates were also blotted with the indicated antibodies. 
Methods

Mice
Animal experiments were approved by the Case Western Reserve University Animal Care and Use Committee. PTPRT KO mice were generated as described previously 8 . PTPRT KI mice were generated as described below. Bothe male and female mice were used.
Generation of PTPRT +/C1400V mutant mice
Fertilized C57Bl/6J mouse eggs were injected with a mixture of Cas9 mRNA, sgRNA and a 122 bp single-stranded DNA oligo. The repair oligo was designed to mutate cysteine 1400 to valine, and destroy the PAM sequence with a synonymous mutation (Extended Data Figure 3 ). The C1400V mutation generated a PmlI site, which was used to genotype founder animals. The knockin allele was confirmed by Sanger sequencing. Correctly targeted founder animals were used to establish and expand lines of mice by crossing them to wild type C57Bl/6J mice.
AOM treatment
Six-week-old mice were injected intraperitoneally once weekly for 6 weeks with 10 mg/kg AOM (Sigma Chemical, St. Louis). Mice were sacrificed 24 weeks after the last AOM injection.
Colons were removed immediately, rinsed with PBS to remove fecal matter, sliced open longitudinally and analyzed for the presence of tumors. Tumors and normal colon tissue were then fixed in 10% formalin overnight to perform histological staining following paraffin embedding.
AOM plus DSS treatment
Eight-week-old mice were injected with a single intraperitoneal 10 mg/kg body weight of azoxymethane (AOM) (Sigma-Aldrich, St Louis, MO, USA). One week later, mice were treated with 2% dextran sulfate sodium (DSS Salt Reagent Grade MW 36,000-50,000, MP Biomedicals, USA) in the drinking water for 7 days, followed by 10 days of regular water. This DSS cycle was repeated 2 times. Animals were sacrificed after 53 days. Colons were removed immediately, rinsed with PBS to remove fecal matter, sliced open longitudinally and analyzed for the presence of tumors. After that, tumors and colon tissue were fixed in 10% formalin overnight to perform histological staining after paraffin embedding.
Cell culture and reagents
HCT116 were obtained from the American Type Culture collection (ATCC, Manassas, VA, USA). The cells were grown in McCoy's 5A + 10% FBS and authenticated by short tandem repeat [STR] profiling. Mycoplasma contamination was routinely checked.
Cell and tissue lysis
Cells or mouse brains were either lysed using a urea lysis buffer (10 mM Tris-HCl, 100 mM 
Virus infection
HCT116 cells were infected with GFP control, PTPRT WT or PTPRT ΔD2 virus for 20 hr and lysed in RIPA buffer as described above.
Protein purification
The D1, D2 or D2CA domains of PTPRT were cloned into the pGEX vector and expressed in BL21 competent bacteria. Protein was purified using the GST-fusion purification protocol. The different fragments of paxillin were cloned into the pET28a vector and expressed in BL21 competent bacteria. Protein was purified using the Qiaexpressionist (Qiagen, Valencia, CA, USA) protocol. Briefly, expression was induced overnight using 0.1mM IPTG, cells were lysed in 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0. Protein was purified from the lysate using Ni-NTA agarose. Purified protein was then dialyzed in PBS using a slide-a-lyzer dialysis cassette (Thermo Fisher Scientific, Waltham, MA, USA).
Nitration of substrate
Recombinant paxillin protein (200 ng/μl) was treated with 2 mM 5,5′-Dithiobis(2-nitrobenzoic acid) and 0.1 mM Diethylenetriaminepentaacetic acid (DTPA) in pH 8.0, 150 mM Tris-HCl buffer and incubated for 30 min at 25°C to protect the sulfhydryl groups of cysteine residues.
Excess reagent and reaction byproducts were removed and the buffer was exchanged to 50 mM Tris-HCl/0.1mM DTPA, pH8.0 using a Microcon-10kDa centrifugal filter unit (Millipore). The protein was then nitrated by adding tetranitromethane (TNM) to a final concentration of 1 mM and incubating for 10 min at 25°C. The nitrated S-protected protein was treated with 10 mM DTT for 1 h at 25°C to de-protect the sulfhydryl groups of cysteine residues and then dialyzed against 50 mM Tris-HCl (pH 7.5) containing 100 mM NaCl at 4°C overnight.
In vitro denitrase assay
PTPRT recombinant proteins (200 ng) were mixed in buffer containing 25mM Tris-HCl, 50mM NaCl and 1:7 diluted HCT116 cell lysate filtered through a 3 KD cut-off spin column to get rid of large molecular weight materials, which provides necessary co-factors. The reactions were pre-incubated for 30 min at 25°C. Nitrated-paxillin substrates (200 ng) were then added in a total reaction volume of 200 μl and incubated for 15 minutes to 2 hr at 30°C. The mixtures were resolved 10% SDS-PAGE, and proteins were either transferred to nitrocellulose membranes for Western blot analyses or excised for mass spectrometry analyses as described below. Enzymatic kinetics were calculated using the Prism Software (Graphpad).
Enzyme kinetics assay
In-gel digestion
SDS-PAGE gel bands containing paxillin protein were subjected to in-gel digestion with sequencing grade modified trypsin (Promega, WI). Briefly, gel pieces excised from a SDS-PAGE were first washed with 50% acetonitrile in 50 mM ammonium bicarbonate, and then dehydrated with acetonitrile. Before an overnight proteolytic digestion, proteins were reduced with 100 mM DTT in 100 mM ammonium bicarbonate at 25 °C for 30min, and alkylated with 250 mM iodoacetamide in 100 mM ammonium bicarbonate, and incubate for 30 min at 25°C.
After proteolytic digestion, peptides were extracted from the gel with 50% acetonitrile and then re-suspended in 0.1% formic acid after being dried completely under the Speed Vacuum.
Liquid chromatography-tandem mass spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was carried out using a Waters 
